CD20xCD22 CAR T cells display robust activity against tumor cells with different antigen expression. A, Representative cytotoxic activity against Raji (Burkitt lymphoma) cells expressing CD20+CD22+. B and C, Cytotoxic activity against Raji cells expressing CD22+ or CD20+. n = 6. Mean ± SD shown. Unpaired t test was performed. The experiment was repeated three times each with 2 or 3 different donors. D, Heat map showing IFNγ release after overnight incubation at an effector:target ratio of 1:1. The experiment was repeated three times each with 2 or 3 different donors. E, Serial killing assay schematics. F–H, Serial killing assay against CD20+CD22+, CD22+, or CD20+ Raji cells at an effector:target ratio of 5:1. Mean ± SD shown. I–K, Flow cytometry data showing differentiation status of CAR T cells at the end of the serial killing assay. Tn/scm: naïve T cells (CD45RA+CD62L+); Tcm: central memory T cells (CD45RA−CD62L+); Tem: effector memory T cells (CD45RA−CD62L−); Temra: effector memory T cells RA (CD45RA+CD62L−). Mean ± SD shown. n = 3.